Semaglutide seems to be more effective the other GLP-1Ras

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were introduced as treatment options for type 2 diabetes (T2DM) in 2005 (1). They have become popular because of their efficacy and durability in relation to glycaemic control, and their low risk of hypoglycaemia in combination with weight loss in most patients (2,3).